Breaking News, Financial News

Financial Report: AstraZeneca

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AstraZeneca 1Q Revenues: $7 billion (+13%) 1Q Earnings: $1.6 billion (+10%) Comments: Growth in the quarter was driven by combined sales of five key products: Nexium, Seroquel, Crestor, Arimidex and Symbicort, up 17% to $3.6 billion. R&D expenses were $1.2 billion in the quarter, up 36%. In the quarter, the company decided to terminate its licensing and collaboration agreement with AtheroGenics Inc., resulting in charges totaling $83 million....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters